Nebenwirkungen · Pioglitazone Actavis
Pioglitazone Actavis 15 mg tablets Pioglitazone Actavis 30 mg tablets Pioglitazone Actavis 45 mg tablets · Abschnitt 4.8 · PDF-Seite 7
HOS-214490 · Präparat HOS-155342
Adverse reactions reported in excess (> 0.5%) of placebo and as more than an isolated case in patients receiving pioglitazone in double-blind studies are listed below as MedDRA preferred term by system organ class and absolute frequency. Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing incidence and seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-06-01T02:00:00Z · SHA-256 ad23e703c99e588d5e3753a426a2d517a2d2fd35bbce3778e82f258ef487d9a7 · Passage 0812046abd33153b8d3145ca05e2f4ae031f288b2ab9c54d826d088881b242f1 · Zeichen 0–567 im Abschnitt